Literature DB >> 2580183

Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics.

R M Brouwer, P Bolli, P Erné, D Conen, W Kiowski, F R Bühler.   

Abstract

The antihypertensive efficacy of combination therapy with the angiotensin-converting enzyme inhibitor captopril and a diuretic or a calcium antagonist was compared in 16 patients with essential hypertension with a blood pressure of over 160/95 mm Hg having triple drug therapy. While monotherapy with a calcium antagonist--usually verapamil 500 mg/day or nitrendipine 70 mg/day--did not reduce diastolic blood pressure to greater than 95 mm Hg, this goal was achieved in 15 out of 16 patients with the combination of captopril (53 mg/day) and the calcium antagonists in the above dose (151 +/- 4/88 +/- 2 SEM mm Hg) and in 13 out of 16 patients with captopril (84 mg/day) and a diuretic (158 +/- 4/91 +/- 1 mm Hg). There was a direct relationship between intraindividual pressure responses to the two drug combinations (r = 0.88, p less than 0.001). Heart rate was similar and weight lower on the captopril-diuretic combination. Captopril's antihypertensive efficacy can be equally enhanced by calcium antagonists (without affecting renin long term) as by diuretics, which are thought to work by stimulating the renin-angiotensin system. The calcium antagonist-captopril combination may be of particular advantage in hypertensive patients who are otherwise difficult to treat.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580183     DOI: 10.1097/00005344-198507001-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  26 in total

1.  Cost containment for treating hypertension in African Americans: impact of a combined ACE inhibitor-calcium channel blocker.

Authors:  D S Kountz
Journal:  J Natl Med Assoc       Date:  1997-07       Impact factor: 1.798

Review 2.  Resistant hypertension and the Birmingham Hypertension Square.

Authors:  D C Felmeden; G Y Lip
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 3.  Use of nifedipine in hypertension and Raynaud's phenomenon.

Authors:  W Kiowski; P Erne; F R Bühler
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

4.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  A combination of verapamil, captopril, and diuretic in the treatment of severe hypertension.

Authors:  F Pasanisi; A L Ferrara; T Marotta
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 6.  Preclinical studies on angiotensin converting enzyme inhibitors.

Authors:  I L Natoff
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 7.  Antihypertensive treatment according to age, plasma renin and race.

Authors:  F R Bühler
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

8.  Inhibition of Autophagy by Captopril Attenuates Prion Peptide-Mediated Neuronal Apoptosis via AMPK Activation.

Authors:  Ji-Hong Moon; Jae-Kyo Jeong; Jeong-Min Hong; Jae-Won Seol; Sang-Youel Park
Journal:  Mol Neurobiol       Date:  2018-10-05       Impact factor: 5.590

Review 9.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

Review 10.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.